13F Holdings
中文EN

AVTX Avalo Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534120 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-77.1%
TTM net income YoY-11.4%
TTM EPS YoY81.6%
Revenue 3-yr CAGR-56.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15,536.1%
Net margin-7,965.8%
FCF margin-11,123.8%
EBITDA margin-15,497.7%

Returns

ROE-50.1%
ROA-40.9%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets11.7%
Debt / equity0.00x
Current ratio19.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio16.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$59,000$441,000$1.92M$18.05M$5.40M
Cost of revenue——$1.28M$3.43M$1.49M
Gross profit——$640,000$14.62M$3.91M
R&D expense$50.08M$24.44M$13.78M$31.31M$59.84M
SG&A expense$22.90M$17.24M$10.30M$20.71M$24.66M
Operating income-$72.92M-$68.51M-$27.35M-$37.44M-$82.13M
Pretax income-$78.09M-$35.02M-$31.53M-$41.63M—
Income tax$165,000$114,000$14,000$28,000-$196,000
Net income-$78.26M-$35.13M-$31.54M-$41.66M-$84.38M
EBITDA-$72.58M-$68.34M-$27.19M-$37.27M-$80.48M
EPS (basic)-5.84-7.94-113.58-1,063.00—
EPS (diluted)-5.84-20.91-113.58-1,063.00—
Weighted avg. shares (diluted)13.40M7.50M277,72739,202—
Balance sheet
Cash & equivalents$15.86M$134.70M$7.55M$13.32M$54.86M
Short-term investments$82.48M$0———
Receivables———$0—
Inventory——$0$20,000$38,000
Current assets$105.29M$138.89M$8.39M$16.42M$61.84M
Goodwill$10.50M$10.50M$10.50M$14.41M$14.41M
Intangibles———$0$38,000
Total assets$116.46M$150.73M$20.99M$33.37M$80.21M
Current liabilities$12.94M$6.96M$4.62M$22.11M$19.89M
Total liabilities$33.41M$17.70M$13.69M$44.28M$57.13M
Shareholders' equity$83.05M$133.03M$7.30M-$10.91M$23.08M
Shares outstanding18.51M10.47M801,74639,2949.40M
Cash flow statement
Operating cash flow-$51.46M-$49.06M-$30.68M-$26.75M-$70.89M
Capital expenditure—$0$158,000$0$113,000
Free cash flow—-$49.06M-$30.84M-$26.75M-$71.00M
Investing cash flow-$81.72M$356,000-$133,000-$95,000-$113,000
Financing cash flow$14.59M$175.85M$25.04M-$14.70M$106.76M
Depreciation & amortization$344,000$169,000$158,000$166,000$1.66M
Stock-based compensation$13.62M$5.85M$3.48M$7.55M$8.17M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.